FDA Updates: Retina Trials and Regulatory Pathways

William M. Boyd, MD, director of the FDA’s Division of Ophthalmology, discussed the agency’s evolving approaches to clinical evidence, trial design, and expedited regulatory pathways at the 2026 Retina World Congress meeting.

• By

• Matthew Solan, senior writer

• Matthew Solan, senior writer

• Matthew Solan, senior writer

• May 14, 2026

• 6 min

• Retinal Physician